Cambridge, MA-based gene editing company Editas Medicine (NASDAQ: EDIT) has named Charles Albright its chief scientific officer. Albright was most recently the VP of genetically defined diseases and genomics at Bristol-Myers Squibb, and held positions at Incyte and DuPont Pharmaceuticals before that.
Sponsored · Video
A Fireside Chat with Fish & Richardson Principal Teresa Lavoie
Fish & Richardson
Sponsored · Whitepaper
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems
Sponsored · Special Report
Hyperinflation in rents is over
Hughes Marino
